New drugs review program (ndrp) knowledge management (KM) capabilities development.
Ended Awarded Last action
- Contract number
- 75F40122F19003
- Awardee
-
Deloitte Consulting LLP UEI CKV2L9GZKJK3
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $939,046
Award facts
- Opportunity
-
- FDARFCOP1251021 Solicitation number
- Contract value 100% obligated
- $939,045.53 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541512 Computer Systems Design Services
- PSC
- R699 Support- Administrative: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Labor Hours
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Clinger-Cohen Act FAR part 39
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$442 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $249,749 | |
| Original award | $689,739 |
About this award
The Food and Drug Administration awarded Deloitte Consulting LLP a Blanket Purchase Agreement (BPA) call valued at $939,045.53 for the New Drugs Review Program (NDRP) Knowledge Management (KM) Capabilities Development initiative. This contract, issued on July 28, 2022, with an ultimate completion date of September 16, 2025, is a child contract under the FDA's $500 million BPA for data and analytics modernization. The work was performed in Silver Spring, Maryland, where the FDA's Center for Drug Evaluation and Research operates, and utilized a labor-hours pricing model. No small business set-aside was designated for this award.
This modification to the contract is intended to de-obligate remaining funds and close out the engagement. Through this effort, Deloitte supported the FDA's knowledge management capabilities within the new drug review program, leveraging its expertise in data analytics and technology modernization. The contract reflects Deloitte's ongoing partnership with the FDA as a prime contractor on significant federal initiatives and demonstrates the company's role in supporting mission-critical regulatory operations within the pharmaceutical review domain.
Quick answers
Who was awarded contract 75F40122F19003?
75F40122F19003 was awarded to Deloitte Consulting LLP by Food and Drug Administration (Department of Health and Human Services) on July 28, 2022.
How much is contract 75F40122F19003 worth?
The government has obligated $939,046 on 75F40122F19003.
Is contract 75F40122F19003 an order under another contract?
Yes. 75F40122F19003 is a BPA call under GS35F0617Y-75F40122A00001, a blanket purchase agreement, on Multiple Award Schedule (MAS).
Was contract 75F40122F19003 competed?
The extent of competition for 75F40122F19003 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award